|
SocialPicks Sentiment:
N/A
** not enough data to be rated
|
This Quarter's Sentiment:
|
|
|
From the Blogosphere
AstraZeneca Beats, Raises – Analyst Blog
|
|
|
AstraZeneca’s (AZN) third quarter earnings came in at $1.68 per American Depositary Shares (ADS), well above the Zacks Consensus Estimate of $1.36 and $1.32 reported in the year-ago period. Revenues increased 10% at constant exchange rates (CER) to $8.2 billion compared to the same period last year.
The primary reasons for the increase in revenues were strong US sales of Toprol-XL benefiting from generic withdrawal, US sales of its H1N1 vaccine and robust growth in emerging markets.
AstraZeneca recorded strong sales across all geographies. Sales in North America, Emerging Markets and Estab...
|
Top 40 Rated Emerging Bio-Pharma Stocks
|
|
|
The accompanying table [click to enlarge] highlights the Top 40 Rated stocks (sorted alphabetically) in the ETF Innovators [ETFI] Emerging Bio-Pharma Index of biotech and pharmaceutical companies with market caps of $200M-$1.5B. The rating system factors in each company's number of innovative clinical pipeline + marketed products, market cap weighting, and historical stock price return.
The Emerging Bio-Pharma Index has outpaced benchmark ETFs such as iShares Nasdaq Biotech (IBB), PowerShares Dynamic Pharma (PJP), and the Healthcare Sector SPDR (XLV) over the past year. Since I last updated ...
|
Top 40 Rated Emerging Bio-Pharma Stocks
|
|
|
The accompanying table [click to enlarge] highlights the Top 40 Rated stocks (sorted alphabetically) in the ETF Innovators [ETFI] Emerging Bio-Pharma Index of biotech and pharmaceutical companies with market caps of $200M-$1.5B. The rating system factors in each company's number of innovative clinical pipeline + marketed products, market cap weighting, and historical stock price return.
The Emerging Bio-Pharma Index has outpaced benchmark ETFs such as iShares Nasdaq Biotech (IBB), PowerShares Dynamic Pharma (PJP), and the Healthcare Sector SPDR (XLV) over the past year. Since I last updated ...
|
Pfizer Needs Isis More Than Isis Needs Pfizer
|
<> In January of 2007, shortly after Isis (ISIS) announced its multibillion dollar, collaboration with Genzyme (GENZ), I chided an executive of Pfizer (PFE), asking how they could let rival Genzyme outbid them for the rights to Mipomersen. He (correctly) pointed out that the mode of delivery was the key factor in their decision. Mipomersen is initially slated to be given by injection (albeit weekly) for Homozygous Familial Hypercholesterolemia, although an oral formulation will probably be available for the larger 1.5 to 2 million heterogeneous and poorly controlled hyperlipidemic patient p...
|
Unusual 11 Mid-Day Movers 4/9: EPMD, ONCY, SPR, XRM Higher; MNKD, NRGN, NKTR, PTRY Lower
|
EP MedSystems, Inc. (NASDAQ: EPMD) 102% HIGHER; St. Jude Medical, Inc. (NYSE: STJ) will acquire the company for $3.00 per share. MannKind Corp. (NASDAQ: MNKD) 60.9% LOWER; Warning from Pfizer on inhaled insulin causing lung cancer. Neurogen Corporation (Nasdaq: NRGN) 31.8% LOWER; today announced it has entered into definitive agreements for a private placement offering of exchangeable preferred stock and warrants with selected institutional investors for gross proceeds of approximately $30.6 million before fees and expenses.Nektar Therapeutics (NASDAQ: NKTR) 28.4% LOWER; Ceased all negotiat...
|
|
ROCK-STAR INVESTORS
|
|
POPULAR STOCKS
|
|
TODAY'S HEADLINES
|
|
TODAY'S TOP PICKS
|
|
|
| StreetInsider.com on NKTR |
Visit streetinsider.com
Be the first to start a discussion and earn 2 points.
More Resources
|
About Nektar Therapeutics
- Answers.com
